Literature DB >> 3100637

A novel pathway of human T cell activation via a 103 kD T cell activation antigen.

B Fleischer.   

Abstract

A novel triggering signal for human proliferating and cytotoxic T lymphocytes defined by a 103 kD T cell-specific activation antigen (Tp103) is described. Tp103 is expressed on all proliferating normal T cells but is not present, or present only in low amounts, on resting peripheral blood T lymphocytes. Cross-linking of T cell and Fc receptor-positive accessory or target cells by an antibody against Tp103 leads to activation of the T cell. The proliferative response is due to an autocrine IL 2-dependent mechanism and can be inhibited by antibodies against the IL 2 receptor or by Cyclosporin A. Resting Tp103-positive T cells also respond to anti-Tp103. Although Tp103 is not linked to the antigen receptor/T3 complex, triggering via Tp103 can be inhibited by modulation of the T3 molecule. Thus, Tp103 defines a new antigen-independent pathway of T cell activation that can be regulated via other T cell surface structures.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3100637

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO.

Authors:  T Ishii; K Ohnuma; A Murakami; N Takasawa; S Kobayashi; N H Dang; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

2.  Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase.

Authors:  M Hegen; J Kameoka; R P Dong; S F Schlossman; C Morimoto
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

3.  Lamina propria T cell activation: role of the costimulatory molecule CD2 and its cytoplasmic tail for the regulation of proliferation and apoptosis.

Authors:  Sven Henschke; Nina N Pawlowski; Martin K Wild; Anton J Kroesen; Martin Zeitz; Jörg C Hoffmann
Journal:  Int J Colorectal Dis       Date:  2005-08-23       Impact factor: 2.571

4.  Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15.

Authors:  T Yamabe; K Takakura; K Sugie; Y Kitaoka; S Takeda; Y Okubo; K Teshigawara; J Yodoi; T Hori
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

5.  Functional phenotype of transformed human alphabeta and gammadelta T cells determined by different subgroup C strains of herpesvirus Saimiri.

Authors:  H Fickenscher; C Bökel; A Knappe; B Biesinger; E Meinl; B Fleischer; B Fleckenstein; B M Bröker
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  High expression of CD26 accurately identifies human bacteria-reactive MR1-restricted MAIT cells.

Authors:  Prabhat K Sharma; Emily B Wong; Ruth J Napier; William R Bishai; Thumbi Ndung'u; Victoria O Kasprowicz; Deborah A Lewinsohn; David M Lewinsohn; Marielle C Gold
Journal:  Immunology       Date:  2015-03-29       Impact factor: 7.397

7.  The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity.

Authors:  T Tanaka; J Kameoka; A Yaron; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

8.  Dipeptidyl aminopeptidase IV from Stenotrophomonas maltophilia exhibits activity against a substrate containing a 4-hydroxyproline residue.

Authors:  Yoshitaka Nakajima; Kiyoshi Ito; Tsubasa Toshima; Takashi Egawa; Heng Zheng; Hiroshi Oyama; Yu-Fan Wu; Eiji Takahashi; Kiyoshi Kyono; Tadashi Yoshimoto
Journal:  J Bacteriol       Date:  2008-09-26       Impact factor: 3.490

9.  CD26 induces T-cell proliferation by tyrosine protein phosphorylation.

Authors:  E Muñoz; M V Blazquez; J A Madueño; G Rubio; J Peña
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

10.  Involvement of dipeptidyl peptidase IV in an in vivo immune response.

Authors:  T Kubota; G R Flentke; W W Bachovchin; B D Stollar
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.